Over 11,100 bottles of bisoprolol fumarate/hydrochlorothiazide (Ziac) were recalled after being contaminated with trace amounts of cholesterol drug ezetimibe—a manufacturing error classified as “low risk” by the FDA. The same Glenmark Pharma facility had previously received an FDA warning for failing to investigate manufacturing discrepancies, suggesting systemic issues in drug production. This incident follows multiple recalls in 2025, including 500,000 prazosin capsules (cancer-causing impurity), 140,000 atorvastatin bottles (failed dissolution tests), and 88,000 carvedilol bottles (carcinogenic chemicals). While the FDA claims contamination poses minimal health risks, patients experience anxiety knowing their trusted medications were improperly made—eroding confidence in Big Pharma. The article highlights that lifestyle…

Newswire

Features

The Latest